JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...